STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

Looking ahead, STAAR Surgical anticipates ICL sales outside China to grow by ... particularly the upcoming launch of EVO Plus in China. During the earnings call, analysts focused on the challenges ...

Understanding the gray zone can greatly help the accuracy of this important measurement in sizing for the EVO ICL (STAAR Surgical). My preference is a mid-gray zone to mid-gray zone measurement ...

Helen K. Wu, MD, said the latest-generation EVO ICL (STAAR Surgical) has a lot of advantages but comes with challenges related to vault, which can be influenced by anatomy and the size of the ICL.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

LAKE FOREST, Calif., February 11, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, ...

LAKE FOREST, Calif., February 11, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

(RTTNews) - Shares of STAAR Surgical Company ... and sells these lenses under the "EVO" family for refractive surgery to treat myopia (nearsightedness). ICL sales were $46.9 million for the ...

Greetings and welcome to the STAAR Surgical Fourth Quarter 2024 Earnings ... our STAAR colleagues for their tireless work to drive EVO ICL sales position as the choice for refractive vision ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership ...